SAIPARENT

What Sai Parenterals promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 12 tracked 0 delivered 1 missed 11 open
  • Working Capital as % of Additional Revenue went quiet said Q4 FY26 Promised: About 25% to 30% of additional revenues as the working capital requirement. Q1 FY27: This guidance was not mentioned or updated in the Q1 FY27 earnings call.
  • Noumed Australian Facility Operational Status delayed said Q4 FY26 Promised: Australian manufacturing facility becomes operational in Q4 FY '27 Q1 FY27: The timeline has been clarified: physical completion is targeted for January 2027, but Phase 1 manufacturing is now expected from April 2027, which is Q1 FY28. This marks a slight delay from the original 'operational in Q4 FY27' guidance.
  • FY27 Consolidated Revenue on track said Q4 FY26 Promised: INR750 crores for the financial year '27 Q1 FY27: Management reiterated the full-year guidance of Rs. 750 crores in revenue for FY27. Q1 revenue of Rs. 182 crores represents 24% of the target, which management states is ahead of schedule given an expected 45:55 H1:H2 revenue split.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 12 tracked commitments for Sai Parenterals — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens